Skip to content
DataLookout
Menu

LEGENDNCT07917104

Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After Resection

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Recurrence-Free Survival (RFS)
Timeframe: From randomization through the end of the two-year postoperative follow-up.

Secondary (10)

Overall Survival (OS)
Postoperative ctDNA Methylation Positivity Rate
Agreement Between ctDNA Methylation Status and Imaging Findings
Lead Time From ctDNA Methylation Positivity to Imaging-Confirmed Recurrence
Secondary No Evidence of Disease (NED) Conversion Rate
Show 5 moreShow less
ctDNA Methylation Clearance Rate
Time to ctDNA Methylation Clearance
ctDNA Methylation Test Reporting Turnaround Time
Patient-reported Quality of Life
Incremental Cost-Effectiveness Ratio (ICER)

Arms and interventions

ctDNA Methylation-Guided TreatmentExperimental
Conventional TreatmentActive comparator

Combination products: Circulating Tumor DNA Methylation Testing

Other: Conventional Postoperative Treatment Strategy

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China